DivestmentJul 22, 2026, 06:06 AM
Windtree Sells CV Drug Candidates; Entitled to 20% Future Proceeds
AI Summary
Windtree Therapeutics has sold its cardiovascular drug candidates to Seismic Pharmaceutical Operations, LLC. The agreement grants Windtree 20% of future proceeds, including global commercial net revenue if approved for acute heart failure. Windtree also receives a $700,000 payment if SPO secures at least $10 million in financing and transfers certain development payables, reducing its funding obligations while retaining potential upside.
Key Highlights
- Sold cardiovascular drug candidates to Seismic Pharmaceutical Operations, LLC.
- Entitled to 20% of any future proceeds received by the buyer.
- Will receive a $700,000 payment if buyer secures at least $10 million in financing.
- Transferred certain cardiovascular drug candidate development payables to the buyer.
- Received an initial cash payment of $150,000 at closing.
- Has the right to sell future licensing payment obligations for $1,200,000.
- Ownership of the Taiwanese Subsidiary will transfer to the buyer effective January 1, 2026.
Price Impact